You Position: Home > Paper
LONG- TERM OUTCOME OF HEGH- DOSE CYTARABINE- BASED CONSOLIDATION CHEMOTHERAPY FOR CHILDHOOD WITH ACUTE MYELOGENOUS LEUKEMIA
( views:258, downloads:40 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1009-9921.2004.04.005
- Key Word:
- 大剂量阿糖胞苷;儿童急性髓性白血病;强化治疗
Abstract： 目的:应用大剂量阿糖胞苷(HDAra-C)在儿童急性髓细胞性白血病(AML)缓解后强化治疗,并观察远期疗效.方法:共44例AML(除M3外),其中HDAra-C治疗组21例(男14例,女7例),中位年龄8.58岁;对照组23例(男15例,女8例),中位年龄6.5岁;亚型:治疗组M13例,M2a5例,M2b2例,M4a4例,M4b例,M51例;对照组:M15例,M29例,M48例,M51例.两组均给予相同方案诱导和巩固治疗后分组行骨髓抑制性强化治疗.结果:1疗程CR37/44例(84.1%),2疗程CR 8/44例(18.1%).治疗组1/21例完成2疗程后失访;16/20例(80%)CCR,其中13例(65%)已停药2a～5a;2/20例(10.0%)复发;2/20例(10.0%)严重感染死亡;对照组3/23例失访和放弃;10/20例(50%)完成全疗程并停药(最长15 a);9/20例(45%)复发;1例严重感染死亡.结论:HDAra-C在儿童AML作缓解后强化治疗,总疗程短,远期疗效好.但骨髓抑制严重,应积极预防和控制以降低治疗相关死亡率.
- [1]E, Morra,M, Lazzarino,E, Brusamolino,etc.The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.[J].1993,72(2).
- [2]张之南.血液病诊断及疗效标准[M].1998.
- [3]何学鹏,杨科.中、大剂量阿糖胞苷治疗急性髓细胞白血病新进展[J].1995,(9).
- [4]Reiter A,Creutzig U,Hermann J,etc.Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93.[J].2001,19(10).
- [5]G, Schiller,J, Gajewski,M, Territo,etc.Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.[J].1992,80(12).